Triage suPARcharged

The suPAR biomarker predicts critical illness across diseases by measuring the level of activation in the immune response.

suPARnostic® is a reliable prognostic tool that enables healthcare professionals to make quick and informed patient triaging decisions at Emergency Departments.

How to interpret suPAR results

Empowering clinical decisions

suPARnostic® empowers healthcare professionals to lead patient triage with confidence by making better-informed decisions backed by reliable biological data across diseases.

Implementing the biomarker suPAR in clinical care delivers faster and safer patient discharges, reduces re-admissions, unnecessary admissions, as well as hospital length-of-stay. – Freeing up critical resources, valuable time, and saving hospital beds for those who need them.

Mikeli one pager photo

STUDY:
Implementing suPAR in triage

Observational study of acute medical patients: suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the Emergency Department.

Improve patient care

Up to 22% reduction in hospital admissions and up to 6% reduction in hospital length-of-stay per patient

improve

Reduce healthcare costs

Up to €100-380 savings per admission depending on medical specialty and geography

reduce

Empower clinical staff

Get more information to make more confident decisions to potentially reduce uncertainty and stress

empower

“it is essential to have the help of biomarkers, such as suPAR, which can support the discharge decision”

Juan González del Castillo,
Dr PhD, Hospital Clínico San Carlos, Spain
suPAR News Vol. 1, April 2019

How suPARnostic® works at the Emergency Department

Step 1

A patient is admitted to the ED for observation

Step 2

The patient’s blood sample is drawn

Step 3

The patient’s suPAR level is measured at the central lab
(~20 minutes) and fits existing hospital workflow.

Step 4

The physician gets the result and makes a triage decision

suPAR is a significant independent predictor of mortality of ED patients

n = 4,343Patients dead after 30 daysPatients alive after 30 daysPPV/NPV
suPAR ≥6 ng/ml133509PPV
20.7%
suPAR >3 and l771,580
suPAR ≤3 ng/ml142,030NPV
99.3%
Sensitivity/Specificity
(suPAR ≤3 versus
≥6 ng/ml)
Sensitivity
90.5%
Specificity
80.0%

Source: Rasmussen LJH, Ladelund S, Haupt TH, et al. Emerg Med J 2016;33:769-775

+700

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates